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Adult murine hosts undergoing induction and regression of primary Moloney
sarcoma virus (MSV) tumors develop antibodies (1-3) and lymphocytes (4-6)
which have activity in vitro against Moloney leukemia virus (MLV)-determined
cell surface antigens on the tumor target cells (7). Antibodies which are able to
lyse the appropriate virus-induced tumor target cells in the presence of
complement appear in two peaks with respect to time after MSV injection (1).
The first peak occurs in the early tumor-bearing animals 10-15 days after MSV
(1). This is followedby a drop in the antibody titers in early regressorswhereafter
the antibodies rise and maintain high titers in long-term regressor animals (1, 8).
The early as well as the late peaks contained cytotoxic activity in both the IgG
and IgM fractions (1). Such MLC-specific antibodies are also active in the
induction of tumor cell destruction in vitro by normal lymphoid cells (8). We
have recently reported that both IgG and IgM were ableto induce cytotoxicity by
nonimmune spleen cells as well as potentiate the cytotoxic activity of immune
spleen cells (9). We now report that IgM from MSV regressor mice will induce
cytotoxicity against the tumor target cells not only by normal spleen cells but by
normal thymocytes and the thymus cell cytotoxicity in combination with IgM
appears to be more efficient than that produced with spleen cells.
Materials and Methods
Source ofAntisera.
￿
AdultBALB/c mice injected with 0.1 ml MSV-M (MSV-B-64, courtesy ofDr.
Jack Gruber, NCI, Bethesda, Md .) developed tumors in 5-8 days which usually regressed by day
20-25. Theserum pooled from 10 such animals at 30 days afterMSV injection was heat inactivated at
56°C andstored at -20°C before use. Serum fractionationwascarried outon Sephadex G-200usinga
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90 x 1.5 cm column as previously described (1, 9). The first half of the leading protein peak was
pooled and reconcentrated to the original serum volume. This fraction was demonstrated to be IgM
by the following assays: immunoelectrophoresis of the 19S fraction with rabbit antiserum against
whole mouse serum (Hoechst Pharmaceuticals, Inc., Kansas City, Mo.) gave a single band in the IgM
region . Furthermore, on immunodiffusion against goat antimouse IgM and goat antimouse IgG
(Cappel Laboratories, Inc ., Downington, Pa.) the 19Speak reacted only with theheavy-chain-specific
anti-IgM.
Cytotoxicity Assays.
￿
Serial dilutions of the antiserum or the above fraction were placed on Ha2
target cells (anMLV antigen possessing in vitro cell line (7, 10) derived from an MSV-induced tumor
of a CBA mouse) which had been seeded 3-4 h previously in wells of microplates (no. 3034, Falcon
Plastics, Div. of BioQuest, Oxnard, Calif.) at a concentration of 200 cells per well. After 1 h
incubation, macrophage-deficient splenocytes or thymocytes prepared as described previously (8),
from adult CBAor BALB/c mice were added to the wells at a concentration of 10,000 cells per well.
The plates were then incubated for 20 h at 37'C in 5% CO, . All dilutions and incubations were done
in minimal essential medium with Earle's salts containing 10% heat-inactivated fetal calf serum, 100
U/ml penicillin and 50 ug/ml streptomycin. The number of target cells remaining in each well was
counted and the log mean t SD of six replicate wells for each dilution was calculated. Comparisons
were made between control wells containing lymphocytes andtest wells containing antibody plus the
same number of lymphocytes. Antibody alone at the same concentrations was also incubated on the
target cells in parallel plates without the addition of lymphocytes as a further control. In order to
determine if lysis was being induced as well as reduction of target cells in the microplate assay, a
chromium release test was performed. Ha2 target cells were labeled with "Cr (Na, CrO,, New
England Nuclear, Boston, Mass.), 100,uCi/10' cells . 2 x 10' labeled target cells were incubated with a
1:320 final dilution of MSV-immune IgM for 1 h followed by the addition of 2 x 10' lymphocytes.
After 24 hincubation at 37'C in 5% CO,, samples ofthe supernates were assayed in agammacounter
to determine "Cr release.
Results
The antibody-induced cell-mediated cytotoxicity as assayed in microcytotox-
icity tests is shown in Table I. This pool of serum from regressor mice induced
100% cytotoxicity in the presence of normal CBA or BALB/c spleen cells which
had been rendered. macrophage deficient (8) before the assay. Both types of
spleen cells produced this level of cytotoxicity to a serum dilution of 1:40.
However, the end point titer using CBA spleen cells was 1:1,280, whereas, it was
only 1:80 with BALB/c spleen cells. The IgM fraction of this antiserum also
induced cytotoxicity by normal CBA spleen cells. As indicated in the table the
maximum cytotoxicity mediated by spleen cells was 34%. This decreased as the
twofold dilutions were made to an end point titer of 1:640 at which the target cell
reduction was 16%. The IgM induced a somewhat different cytotoxicity pattern
with normal thymus cells; maximum reduction of 45% occurred at a dilution of
1:320. The last dilution showing significant target cell reduction was 1:1,280. As
indicated in the table, this IgM incubated on the target cells alone produced no
significant target cell reduction nor did normal serum from an uninfected mouse
in combination with the same number of normal spleen cells.
Results of the chromium release assay are shown in Table II. Using a 1:320
dilution of the IgM fraction, specific chromium release above the level of
spontaneous release was observed only with the combination of IgM and normal
thymus cells. Spleen cells were not induced to be cytotoxic in this test. This is
seemingly in contrast to the microplate assay. However, the optimum dilution of544 LAMON ET AL .
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TABLE I
Antibody-Induced Cell-Mediated Cytotoxicity against Ha2 Target Cells in
Microcytotoxicity Assays
* Sera placed on target cells in nine twofold dilution steps beginning at a dilution of 1:10; MSV 30R indicates serum
from regressor mice 30 days after MSV injection; control serum was taken from an uninfected BALB/c mouse.
$ Macrophage-depleted lymphoid cells, 10,000 per well, prepared as described previously (5, 8, 9) . Thymocytes
contained <2%B cells and >95% T cells by surface Ig and rabbit anti-T-cell (8) serum cytotoxicity, respectively.
§ Control contained lymphocytes alone or medium alone as indicated. Log mean + SD calculated from six
replicates.
11 % reduction calculated by the formula: 100 - (geometric mean of target cells in test wells)/(geometric mean of
target cells in control wells) x 100. Number; shown indicate maximum observed. (-), indicates no significant
reduction.
4 Optimal dilution, numbers shown indicate the reciprocal of the dilution(s) where the maximum reduction
occurred. P values for each of these were <0.0005 except the last two indicated by (-) where no significant
reduction occurred.
** Reciprocal of the end point dilution producing significant (P < 0.05) target cell reduction .
TABLE II
IgM-Induced Thymocyte-Mediated "Cr Release from Labeled Ha2 Cells
Discussion
* IgM from MSV regressor mice 30 days after infection diluted 1 :320.
$ Mean values from triplicate samples.
§ P values derived using a Student's t test to compare the triplicate values for spontaneous release in the medium
control with the combinations shown. Only the IgM plus thymocyte combination produced "Cr release
significantly greater than spontaneous release.
IgM for cytotoxicity by spleen cells was much lower than it was with thymus
cells. As indicated, there was no induction of lysis with either IgM alone or
normal thymus cells alone.
We have thus demonstrated the ability of IgM antibody from MSV regressor
mice to induce cytotoxicity by normal thymus and spleen cells against target
cells bearing the appropriate virally induced antigen(s). In addition to the
specificity controls reported herein, it has been demonstrated repeatedly in our
hands that the antibody and lymphocyte cytotoxicity in this system isspecific for
Ha2 target
cells incubated with*
Mean + SD of
cpm released$
cpm Above spontaneous
release$ P§
Medium 1,177 + 95 -
IgM 1,163 + 112 - -
IgM + thymocytes 1,467 + 80 289 <0.01
Thymocytes 1,113 + 12 - -
IgM + splenocytes 983 + 104 - -
Splenocytes 1,213 + 14 36 >0.25
Sera Lymphocytes$ Target cells in control § Maximum
1~
Optimal
dilutionT Titer**
log,,/mean + SD
MSV 30 Runfractionated CBA spleen 2.002 t 0.07 100 (10-40) 1,280
MSV 30 Runfractionated BALB/c spleen 1 .932 + 0.06 100 (10-40) 80
MSV30 RIgM CBA spleen 1.996 t 0.05 34 10 640
MSV 30 RIgM CBA thymus 2.119 t 0.07 45 320 1,280
MSV 30 RIgM None 1.873 t 0.20 - - <10
Control serum BALB/c spleen 2.395 + 0.06 - - <10LAMON ET AL.
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MLV-determined cell surface antigen(s) (1, 5, 7, 8). Antibody from MSV-
infected hosts will react specifically with MLV-induced lymphoma cells (1) and
with cells which possess both MSV and MLV (S+ L+ cells) (7, 8) such as the
Ha2 cells used in the present experiments, but not with cells which possess only
the defective sarcoma virus and are leukemia negative (S+ L- cells) (7). The
target cell specificity of the immune lymphocytes in this system has also been
repeatedly demonstrated (5, 7, 8, 11-13) . Finally, we have also demonstrated the
target cell specificity of the antibody-dependent cell-mediated cytotoxicityto be
specific for cells possessing MLV-determined cell surface antigen(s) (14).
In many nontumorsystemswhich have been investigated, it has been reported
that IgG induced antibody-dependent cell-mediated cytotoxicity andthatIgM is
not active in such systems (15-17). However, we have found that IgM is capable
of inducing cytotoxicity against target cells bearing the appropriate antigenic
specificities in vitro by normal lymphoid cells as well as potentiating the
cytotoxic activity of immune lymphoid cells (9). Previous investigations,
including those by ourselves, had indicated that thymus-processed lymphocytes
(T cells) were not required for antibody-dependent cell-mediated cytotoxicity (8,
18, 19) and furthermore, that normal T-cell splenic lymphocytes did not appear
to be active in such systems (8). There has been one report, however, indicating
that antibody could induce cytotoxicity by normal rabbit thymus cells (20) . We
are currently investigating the subpopulations of thymus cells and spleen cells
which can be induced to be cytotoxic by IgM and IgG with specificity for the
virally induced antigens on the surface ofthe tumor target cells. Although the in
vivo significance ofthe present findings is unknown, this IgM-inducedthymocyte
cytotoxicity may be one of the factors which produce the high incidence of
spontaneous regression of these primary MSV tumors .
In addition to the implications in this particular tumor model, these findings
may have abroadersignificance in terms ofcellularimmunity in general. SinceT
cells, which by themselves are not cytotoxic, can be induced to be cytotoxic
against target cells coated with IgM, it is conceivable in other situations of
T-cell-dependent in vitro cytotoxicity that IgM with specificity for the target
cells is involved. IgM secreted by bone marrow-derived bursa equivalent-proc-
essed lymphocyte possessing high concentrations of surface Ig (B cells) could
bind to the target cells and induce or potentiate the cytotoxicity of T cells. In
situations where relatively purified populations of T cells have been used, the T
cells could bear IgM originally secreted by B cells. Both situations would require
that a subpopulation of T cells possess IgM Fc receptors. In another series of
experiments, we have in fact found a subpopulation of theta-bearing cells in
mouse thymus which possess IgM Fc receptors (Lamon, E. W., B. Andersson,
H. D. Whitten, M. M. Hurst, and V. Ghanta, unpublished observation and ref-
erence 21).
In summary, we have found that IgM, from mice which have undergone
regression of primary MSVtumors, will induce cytotoxicity against the appropri-
ate target cells by normal splenocytes and normal thymocytes . The thymocyte-
induced cytotoxicity induced by IgM appeared to be more efficient than that
produced by the same number of splenocytes. This was demonstrated by
microcytotoxicity and "Cr-release assays.546
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